[Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].

@article{Bdane1999ToleranceAF,
  title={[Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].},
  author={Christophe B{\'e}dane and Val{\'e}rie Le Brun and Serge Boulinguez and Jean François Berdah and M L Bouyssou and N Delpuget and Philippe Bernard and Nicole Tubiana-Mathieu and J M Bonnetblanc},
  journal={Annales de dermatologie et de venereologie},
  year={1999},
  volume={126 2},
  pages={142-6}
}
BACKGROUND The use of high-dose interferon alpha as adjuvant therapy has been shown for the first time to improve recurrence-free and overall survival in stage II malignant melanoma. The aim of our work was to evaluate the toxicity of this therapeutic scheme during a 1-year period in 13 patients with malignant melanoma. PATIENTS AND METHODS Thirteen patients, mean age 56 years, with stage II melanoma were included. Interferon alpha was administered at the dose of 20 MU per m2 body surface… CONTINUE READING